Harrow's Product Sales Soar 67% in Q2, Driving Strong Growth

Ticker: HROW · Form: 10-Q · Filed: Aug 11, 2025 · CIK: 1360214

Harrow, INC. 10-Q Filing Summary
FieldDetail
CompanyHarrow, INC. (HROW)
Form Type10-Q
Filed DateAug 11, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: Pharmaceuticals, Revenue Growth, Q2 Earnings, 10-Q Filing, Biotech, Investor Insight, Market Performance

Related Tickers: HROW

TL;DR

**Harrow's Q2 product sales exploded, making it a strong buy for growth-focused investors.**

AI Summary

HARROW, INC. reported a significant increase in product sales for the three and six months ended June 30, 2025. Product sales net for the second quarter of 2025 reached $25,000,000, a substantial rise from $15,000,000 in the same period of 2024, representing a 66.7% increase. For the six months ended June 30, 2025, product sales net were $48,000,000, up from $28,000,000 in the prior year, an increase of 71.4%. Other revenues remained consistent at $1,000,000 for both the three and six-month periods in 2025 and 2024. The company's strategic outlook appears focused on continued growth in its pharmaceutical preparations segment, as evidenced by these strong sales figures. While specific net income figures were not provided in the excerpt, the robust revenue growth suggests a positive trajectory. Key business changes include the consistent performance of other revenue streams, indicating stability outside of core product sales. Risks, though not explicitly detailed in this excerpt, would typically involve market competition and regulatory changes inherent in the pharmaceutical industry.

Why It Matters

This substantial revenue growth for HARROW, INC. signals strong market acceptance of its pharmaceutical products, which is crucial for investor confidence and potential stock appreciation. For employees, this growth could mean job security and expansion opportunities within the company. Customers benefit from the continued availability and potential innovation of HARROW's pharmaceutical preparations. In a competitive market, this performance positions HARROW as a growing player, potentially challenging larger pharmaceutical companies and attracting further investment in the sector.

Risk Assessment

Risk Level: medium — While product sales show strong growth, the absence of net income or profitability metrics in this excerpt prevents a full financial assessment. The pharmaceutical industry inherently carries medium risk due to regulatory hurdles, R&D costs, and intense competition, which are not detailed here but are always present for companies like HARROW, INC.

Analyst Insight

Investors should investigate HARROW's profitability metrics, specifically net income and EPS, to confirm if the impressive revenue growth translates to bottom-line success. Consider HROW for a growth-oriented portfolio, but perform due diligence on its debt structure and future product pipeline.

Financial Highlights

revenue
$49,000,000
revenue Growth
+69.1%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$25,000,000+66.7%
Product Sales$48,000,000+71.4%
Other Revenues$1,000,000+0.0%

Key Numbers

Key Players & Entities

FAQ

What were HARROW, INC.'s product sales for Q2 2025?

HARROW, INC.'s product sales net for the second quarter of 2025 were $25,000,000, a significant increase from $15,000,000 in Q2 2024.

How much did HARROW, INC.'s product sales grow year-over-year in Q2?

HARROW, INC. experienced a 66.7% increase in product sales net from $15,000,000 in Q2 2024 to $25,000,000 in Q2 2025.

What were HARROW, INC.'s total product sales for the first six months of 2025?

For the six months ended June 30, 2025, HARROW, INC.'s product sales net totaled $48,000,000, up from $28,000,000 in the same period of 2024.

Did HARROW, INC.'s other revenues change in Q2 2025?

No, HARROW, INC.'s other revenues remained consistent at $1,000,000 for both the three and six-month periods in 2025 and 2024.

What is the primary business of HARROW, INC. based on the filing?

Based on the Standard Industrial Classification, HARROW, INC. operates in 'PHARMACEUTICAL PREPARATIONS [2834]', indicating its focus on pharmaceutical products.

When was HARROW, INC.'s 10-Q filing submitted?

The 10-Q filing for HARROW, INC. was filed on August 11, 2025, with the conformed period of report ending on June 30, 2025.

What is the potential impact of HARROW, INC.'s revenue growth on investors?

The strong revenue growth of HARROW, INC. could signal increased investor confidence and potential stock appreciation, making it an attractive option for growth-oriented portfolios.

What are the general risks associated with HARROW, INC.'s industry?

The pharmaceutical industry, in which HARROW, INC. operates, generally carries medium risk due to factors like regulatory hurdles, high research and development costs, and intense market competition.

What was HARROW, INC.'s previous company name?

HARROW, INC. was formerly known as HARROW HEALTH, INC. until a name change on December 28, 2018, and before that, Imprimis Pharmaceuticals, Inc.

Where is HARROW, INC.'s business located?

HARROW, INC.'s business address is 1A Burton Hills Blvd, Suite 200, Nashville, TN.

Industry Context

HARROW, INC. operates within the Pharmaceutical Preparations industry (SIC 2834). This sector is characterized by significant research and development, stringent regulatory oversight, and competitive market dynamics. Companies often focus on specialized therapeutic areas or drug delivery mechanisms to gain market share.

Regulatory Implications

As a pharmaceutical company, HARROW, INC. is subject to extensive regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards (cGMP), drug approval processes, and marketing regulations is critical. Any lapse in compliance can lead to significant financial penalties, product recalls, and reputational damage.

What Investors Should Do

  1. Monitor gross and operating margins
  2. Analyze the drivers of product sales growth
  3. Evaluate debt levels and cash flow

Key Dates

Glossary

Product Sales Net
The total revenue generated from the sale of the company's products after deducting any returns, allowances, or discounts. (Key metric showing the company's core business performance, which has seen significant growth.)
Other Revenues
Revenue generated from sources other than the company's primary product sales, such as services, licensing, or other miscellaneous income. (Indicates stability in ancillary revenue streams, complementing the growth in product sales.)
10-Q
A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the detailed financial results and operational information for HARROW, INC. for the specified quarter.)

Year-Over-Year Comparison

The current 10-Q filing for the period ending June 30, 2025, shows a significant acceleration in product sales growth compared to the prior year. Q2 2025 product sales increased by 66.7% year-over-year, and year-to-date sales grew by 71.4%. This robust revenue expansion suggests a positive shift in the company's top-line performance. Other revenue streams have remained stable, indicating consistent performance in non-core areas. No new significant risks were detailed in the provided excerpt, but the overall financial trajectory appears strong based on revenue figures.

Filing Stats: 4,461 words · 18 min read · ~15 pages · Grade level 17.9 · Accepted 2025-08-11 16:16:22

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36 Part II OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 39

Signatures

Signatures 40 2 PART I FINANCIAL INFORMATION Item 1. Financial Statements HARROW, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 52,963,000 $ 47,247,000 Accounts receivable, net 78,822,000 116,373,000 Inventories 11,552,000 10,702,000 Prepaid expenses and other current assets 11,553,000 15,329,000 Total current assets 154,890,000 189,651,000 Property, plant and equipment, net 3,512,000 3,734,000 Capitalized software costs, net 1,478,000 1,751,000 Operating lease right-of-use assets, net 8,155,000 8,554,000 Intangible assets, net 176,666,000 184,949,000 Goodwill 332,000 332,000 TOTAL ASSETS $ 345,033,000 $ 388,971,000 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses $ 25,414,000 $ 41,406,000 Accrued rebates and copay assistance 32,154,000 39,900,000 Accrued payroll and related liabilities 6,824,000 9,496,000 Deferred revenue and customer deposits 91,000 44,000 Current portion of notes payable, net of unamortized debt discount 183,619,000 - Current portion of operating lease obligations 782,000 497,000 Total current liabilities 248,884,000 91,343,000 Operating lease obligations, net of current portion 8,366,000 8,792,000 Notes payable, net of unamortized debt discount and current portion 38,484,000 219,539,000 TOTAL LIABILITIES 295,734,000 319,674,000 Commitments and contingencies - - STOCKHOLDERS' EQUITY Common stock, $ 0.001 par value, 50,000,000 shares authorized, 36,714,679 and 35,622,214 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 36,000 35,000 Additional paid-in capital 213,788,000 221,002,000 Accumulated deficit ( 164,170,000 ) ( 151,385,000 ) TOTAL HARROW, INC. STOCKHOLDERS' EQUITY 49,654,000 69,652,000 Noncontrolling interests ( 355,000 ) ( 355,000 )

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing